Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.58 |
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA6 | P23280 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469809 | 1.00 | CA1 (0.58) | CA1CA2CA9MAPK1FTO | |
| Hydrochloric Acid SCHEMBL29970142 | 0.98 | CA1 (0.56) | CA1CA2CA9MAPK1FTO | |
| Formic Acid SCHEMBL14247786 | 0.91 | CA1 (0.50) | CA1CA2CA9MAPK1FTO | |
| SCHEMBL23833632 | 0.83 | MAPK1 (0.46) | CA1CA2CA9MAPK1FTO | |
| SCHEMBL9600144 | 0.82 | GAA (0.43) | CA1CA2CA9MAPK1KDM4E | |
| SCHEMBL1641021 | 0.80 | MAPT (0.42) | CA1CA2CA9MAPK1LMNA | |
| SCHEMBL10480797 | 0.78 | CA1 (0.58) | CA1CA2CA9MAPK1FTO | |
| SCHEMBL9002773 | 0.78 | COMT (0.49) | CA1CA2CA9MAPK1LMNA | |
| SCHEMBL30203439 | 0.78 | CA1 (0.58) | CA1CA2CA9MAPK1FTO | |
| SCHEMBL29673491 | 0.78 | TRPV4 (0.51) | CA1CA2CA9MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-108137555-A | Available for treating the Indolin-2-one derivative of CNS diseases | 豪夫迈·罗氏有限公司 | 2018-06-08 | — | — | CN | claimed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025109563-A1 | SPIRO-HYDANTOIN DERIVATIVE EXHIBITING ADAMTS-4 INHIBITORY ACTIVITY, AND USE THEREOF | 서울대학교병원 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025106383-A1 | PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-5302708-A | Colorfastness | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-04-12 | — | — | US | disclosed |
| EP-0527441-A2 | Water-soluble phthalocyanine dyes, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-02-17 | — | — | EP | disclosed |
| EP-0165753-B1 | HERBICIDAL THIOPHENESULFONAMIDES AND PYRIDINESULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0231837-B1 | PROCESS FOR THE PREPARATION OF WATER SOLUBLE PHTHALOCYANINE DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-02 | — | — | EP | disclosed |
| US-4784684-A | Herbicidal pyridinesulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-15 | — | — | US | disclosed |
| US-4745187-A | Process for the preparation of water-soluble phthalocyanine dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-05-17 | — | — | US | disclosed |
| EP-0231837-A2 | Process for the preparation of water soluble phthalocyanine dyes | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-08-12 | — | — | EP | disclosed |
| US-4668279-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0165753-A2 | Herbicidal thiophenesulfonamides and pyridinesulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CA1 1714/4885CA2 2865/4885CA9 1575/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | CA1 4810/4885CA2 4355/4885CA9 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.